Pancreatic Cancer Research

Journal articlePharm Dev Technol2022

Development of a novel oral complex lipid emulsion containing triptolide for targeting pancreatic cancer.

Journal
Pharm Dev Technol
Published
5 October 2022
Citations
5
Type
Article

These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

abstract license unknown

Triptolide (TP), a diterpenoid triepoxide, exhibits strong anti-cancer activities, especially against pancreatic cancer, but its clinical application is limited by organ toxicity. TP was combined with diammonium glycyrrhizinate (DG), as a cytoprotective agent, in a novel oral complex lipid emulsion (TP/DG-CLE) to increase the therapeutic index of TP against pancreatic cancer. … Excerpt only: this text is the publisher’s. Read it in full at the source.